Thermo Fisher Scientific(TMO) - 2025 Q4 - Earnings Call Transcript

Financial Performance - In Q4 2025, revenue grew 7% year-over-year to $12.21 billion, and adjusted operating income increased 6% to $2.88 billion [5][20] - For the full year 2025, revenue grew 4% to $44.56 billion, with adjusted operating income also growing 4% to $10.11 billion [6][20] - Adjusted EPS for Q4 was $6.57, an 8% increase, while for the full year, it was $22.87, reflecting a 5% growth [6][20] Business Segment Performance - In the Life Sciences Solutions segment, Q4 revenue increased 13% year-over-year, driven by BioProduction, with full-year growth at 8% [28] - The Analytical Instruments segment saw Q4 revenue growth of 1%, with full-year revenue decreasing by 11% [29][30] - Specialty Diagnostics reported a 5% revenue increase in Q4 and a 4% increase for the full year, with adjusted operating income up 19% in Q4 [31] - The Laboratory Products and Biopharma Services segment experienced a 7% revenue increase in Q4 and a 4% increase for the full year [32] Market Performance - In Q4, North America and Asia Pacific grew low single digits, while Europe grew mid-single digits; China experienced a low single-digit decline [22] - For the full year, North America and Asia Pacific also grew low single digits, with China declining mid-single digits [23] Company Strategy and Competitive Position - The company’s growth strategy focuses on high-impact innovation, trusted partnerships, and a strong commercial engine [8][12] - In 2025, the company launched several high-impact products, including advancements in mass spectrometry and bioreactor technologies [9][10] - Strategic partnerships, including collaborations with the Chan Zuckerberg Institute and OpenAI, aim to enhance capabilities and improve productivity [12] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 from a position of strength, with a revenue guidance range of $46.3 billion to $47.2 billion, indicating 4%-6% growth [19][33] - The company anticipates organic growth of 3%-4% for 2026, with adjusted EPS guidance of $24.22-$24.80, reflecting 6%-8% growth [19][33] Other Important Information - The company deployed approximately $16.5 billion in 2025, including $13 billion for M&A and $3.6 billion returned to shareholders [13][26] - The acquisition of Clario, expected to close by mid-2026, is anticipated to be accretive to adjusted EPS by approximately $0.45 in the first year [15][27] Q&A Session Summary Question: Insights on 2026 guidance and market conditions - Management indicated that the guidance assumes similar market conditions to 2025, with expectations for gradual improvement in organic growth [45][47] Question: Sentiment in biopharma spending - Management noted positive sentiment in pharma and biotech, with expectations for improved spending plans in 2026 [53][56] Question: Industry supply and demand dynamics in Pharma Services - Management highlighted strong demand in sterile fill finish and the strategic acquisition of a New Jersey site to expand capacity [61][62] Question: Competitive advantage in the research and safety market - Management confirmed stable competitive dynamics and continued share gains in the research and safety market [64]